The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
AASLD guidelines for treatment of chronic hepatitis B
Open accessAbstract
Potential conflict of interest: Dr. Jonas consults and received grants from Gilead. She received grants from Bristol‐Myers Squibb and Roche. Dr. Chang advises Genentech, Alnylam, and Arbutus. Dr. Terrault consults for Bristol‐Myers Squibb and received grants from Gilead. Dr. Bzowej received grants from Gilead, Synageva, and Ocera. The funding for the development of this Practice Guideline was provided by the American Association for the Study of Liver Diseases. This Practice Guideline was approved by the AASLD on August 1, 2015. This Practice Guideline published with accompanying Reviews by Lok et al., Jonas et al., and Brown et al. See Editorial on Page 31 Objectives and Guiding Principles Guiding Principles This document presents official recommendations of the American Association for the Study of Liver Diseases (AASLD) on the treatment of chronic hepatitis B (CHB) virus (HBV) infection in adults and children. Unlike previous AASLD practice guidelines, this guideline was developed in compliance with the Institute of Medicine standards for trustworthy practice guidelines and uses the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach.1 Multiple systematic reviews of the literature were conducted to support the recommendations in this practice guideline. An enhanced understanding of this guideline will be obtained by reading the applicable portions of the systematic reviews. This guideline focuses on using antiviral therapy in chronic HBV infection and does not address other related and important issues, such as screening, prevention, and surveillance. For broader issues related to diagnosis, surveillance, and prevention as well as treatment in special populations (e.g., liver transplant recipients) that are not addressed by this guideline, the previous AASLD guideline2 and recent World Health Organization (WHO) guideline3 are excellent additional resources. Objectives Guideline developers from the AASLD formulated a list of discrete questions that physicians are faced with in daily practice. These questions were: Should adults with immune active CHB be treated with antiviral therapy to decrease liver‐related complications? Should adults with immune‐tolerant infection be treated with antiviral therapy to decrease liver‐related complications? Should antiviral therapy be discontinued in hepatitis B e antigen (HBeAg)‐positive persons who have developed HBeAg seroconversion on therapy? Should antiviral therapy be discontinued in persons with HBeAg‐negative infection with sustained HBV DNA suppression on therapy? In HBV‐monoinfected persons, does entecavir therapy, when compared to tenofovir therapy, have a different impact on renal and bone health? Is there a benefit to adding a second antiviral agent in persons with persistent low levels of viremia while being treated with either tenofovir or entecavir? Should persons with compensated cirrhosis and low levels of viremia be treated with antiviral agents? Should pregnant women who are hepatitis B surface antigen (HBsAg) positive with high viral load receive antiviral treatment in the third trimester to prevent perinatal transmission of HBV? Should children with HBeAg‐positive CHB be treated with antiviral therapy to decrease liver‐related complications? Target Audience This guideline is intended primarily for health care professionals caring for patients with CHB. Additionally, this guideline may assist policy makers in optimizing the care of individuals living with CHB. Background Burden of Disease Globally, an estimated 240 million persons have CHB with a varying prevalence geographically, highest in Africa and Asia.4 In the United States, the National Health and Nutrition Examination Survey (1999 to 2008) identified approximately 704,000 adults with CHB,5 but with adjustments for hepatitis B infection among foreign‐born persons, the upper estimate of CHB in the United States may be as high as 2.2 million.6 Globally, deaths from cirrhosis and hepatocellular carcinoma (HCC) were estimated at 310,000 and 340,000 per year, respectively.7 To reduce the morbidity and mortality of CHB in the United States and worldwide, there is a need for continued efforts to identify infected individuals through targeted screening, prevent new infections through vaccination, and monitor and treat those at risk for complications of their CHB, including surveillance for HCC.8 Natural History in Adults and Children CHB has been traditionally characterized into four phases (Table 1), reflecting the dynamic relationship between viral replication and evolution and the host immune response. These phases are of variable duration and not every person infected with CHB will evolve through all phases. Given the dynamic nature of CHB infection, serial monitoring of HBV DNA and alanine aminotransferase (ALT) levels is important to characterize the phase of infection. A single ALT and HBV DNA level are insufficient to assign phase of infection and/or need for tre
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
Ott, J. J., Stevens, G. A., Groeger, J., & Wiersma, S. T. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.116 · Cited by 1,843
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load
Iloeje, U. H., Yang, H., Su, J., Jen, C., You, S., & Chen, C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.016 · Cited by 1,528
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
Lau, G. K. K., Piratvisuth, T., Luo, K. X., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M. W., Chow, W. C., Paik, S. W., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043470 · Cited by 1,519
Updated definitions of healthy ranges for serum alanine aminotransferase levels
Prati, D., Taioli, E., Zanella, A., Torre, E. D., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00006 · Cited by 1,445
A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051285 · Cited by 1,444
Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma
Yang, H.-I., Lu, S.-N., Liaw, Y.-F., You, S.-L., Sun, C.-A., Wang, L.-Y., Hsiao, C. K., Chen, P.-J., Chen, D.-S., & Chen, C.-J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013215 · Cited by 1,222
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Lai, C.-L., Shouval, D., Lok, A. S., Chang, T.-T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R. C., Cross, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051287 · Cited by 1,188
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Marcellin, P., Heathcote, E. J., Buti, M., Gane, E., de Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802878 · Cited by 1,181
Janssen, H. L., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U. S., Cakaloglu, Y., Simon, C., So, T. M., Gerken, G., de Man, R. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17701-0 · Cited by 1,162
Marcellin, P., Lau, G. K. K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., Lu, Z.-M., Piratvisuth, T., Germanidis, G., Yurdaydin, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040431 · Cited by 1,145
Chang, T.-T., Liaw, Y.-F., Wu, S.-S., Schiff, E., Han, K.-H., Lai, C.-L., Safadi, R., Lee, S. S., Halota, W., Goodman, Z., et al. (2010) · Hepatology · doi:10.1002/hep.23785 · Cited by 972
The natural history of chronic hepatitis B virus infection #
McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.22898 · Cited by 876
Weinbaum, C. M., Mast, E. E., & Ward, J. W. (2009) · Hepatology · doi:10.1002/hep.22882 · Cited by 815
Chang, T.-T., Lai, C.-L., Yoon, S. K., Lee, S. S., Coelho, H. S. M., Carrilho, F. J., Poordad, F., Halota, W., Horsmans, Y., Tsai, N., et al. (2010) · Hepatology · doi:10.1002/hep.23327 · Cited by 588
Tseng, T., Liu, C., Yang, H., Su, T., Wang, C., Chen, C., Kuo, S. F., Liu, C., Chen, P., Chen, D., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.007 · Cited by 574
Cooper, R. D., Wiebe, N., Smith, N., Keiser, P., Naicker, S., & Tonelli, M. (2010) · Clinical Infectious Diseases · doi:10.1086/655681 · Cited by 565
Lok, A. S. F., McMahon, B. J., Brown, R. S., Wong, J. B., Ahmed, A. T., Farah, W., Almasri, J., Alahdab, F., Benkhadra, K., Mouchli, M. A., et al. (2016) · Hepatology · doi:10.1002/hep.28280 · Cited by 552
Self-citationYim, H. J., & Lok, A. S.-F. (2006) · Hepatology · doi:10.1002/hep.20956 · Cited by 545
Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Ma, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042957 · Cited by 531
Schwimmer, J. B., Dunn, W., Norman, G. J., Pardee, P. E., Middleton, M. S., Kerkar, N., & Sirlin, C. B. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.052 · Cited by 498
Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
Heathcote, E. J., Marcellin, P., Buti, M., Gane, E., De Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.011 · Cited by 462
Kowdley, K. V., Wang, C. C., Welch, S., Roberts, H., & Brosgart, C. L. (2012) · Hepatology · doi:10.1002/hep.24804 · Cited by 400
Buster, E. H. C. J., Hansen, B. E., Lau, G. K. K., Piratvisuth, T., Zeuzem, S., Steyerberg, E. W., & Janssen, H. L. A. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.061 · Cited by 393
Buster, E. H. C. J., Flink, H. J., Cakaloglu, Y., Simon, K., Trojan, J., Tabak, F., So, T. M. K., Feinman, S. V., Mach, T., Akarca, U. S., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.031 · Cited by 393
Perinatal transmission of hepatitis B virus: an Australian experience
Wiseman, E., Fraser, M. A., Holden, S., Glass, A., Kidson, B. L., Heron, L. G., Maley, M. W., Ayres, A., LOCARNINI, S. A., & Levy, M. T. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02524.x · Cited by 378
Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence
Hall, A. M., Hendry, B. M., Nitsch, D., & Connolly, J. O. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.01.022 · Cited by 373
Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B
Gish, R. G., Lok, A. S., Chang, T., de Man, R. A., Gadano, A., Sollano, J., Han, K., Chao, Y., Lee, S., Harris, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.025 · Cited by 367
Zou, H., Chen, Y., Duan, Z., Zhang, H., & Pan, C. (2012) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2011.01492.x · Cited by 366
Weinbaum, C. M., Williams, I., Mast, E. E., Wang, S. A., Finelli, L., Wasley, A., Neitzel, S. M., & Ward, J. W. (2008) · PubMed · Cited by 364
Hadziyannis, S. J., Sevastianos, V., Rapti, I., Vassilopoulos, D., & Hadziyannis, E. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.039 · Cited by 347
The clinical significance of persistently normal ALT in chronic hepatitis B infection
Lai, M., Hyatt, B. J., Nasser, I. A., Curry, M. P., & Afdhal, N. H. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.07.022 · Cited by 335
Fattovich, G. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05474-6 · Cited by 333
Brown, R. S., McMahon, B. J., Lok, A. S. F., Wong, J. B., Ahmed, A. T., Mouchli, M. A., Wang, Z., Prokop, L. J., Murad, M. H., & Mohammed, K. (2016) · Hepatology · doi:10.1002/hep.28302 · Cited by 324
Self-citationLiaw, Y.-F., Sheen, I.-S., Lee, C.-M., Akarca, U. S., Papatheodoridis, G. V., Wong, F. S.-H., Chang, T.-T., Horban, A., Wang, C., Kwan, P., et al. (2011) · Hepatology · doi:10.1002/hep.23952 · Cited by 316
Marcellin, P., Bonino, F., Lau, G. K. K., Farci, P., Yurdaydin, C., Piratvisuth, T., Jin, R., Gurel, S., Lu, Z.-M., Wu, J., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.03.006 · Cited by 315
Buti, M., Tsai, N., Petersen, J., Flisiak, R., Gurel, S., Krastev, Z., Aguilar Schall, R., Flaherty, J. F., Martins, E. B., Charuworn, P., et al. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3486-7 · Cited by 297
Chu, C., Hung, S.-J., Lin, J., Tai, D., & Liaw, Y. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.12.040 · Cited by 287
Chon, Y. E., Choi, E. H., Song, K. J., Park, J. Y., Kim, D. Y., Han, K.-H., Chon, C. Y., Ahn, S. H., & Kim, S. U. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044930 · Cited by 283
Side effects of long-term oral antiviral therapy for hepatitis B
Fontana, R. J. (2009) · Hepatology · doi:10.1002/hep.22885 · Cited by 272
Hui, C., Leung, N., Yuen, S., Zhang, H., Leung, K., Lu, L., Cheung, S. K. F., Wong, W., & Lau, G. K. (2007) · Hepatology · doi:10.1002/hep.21724 · Cited by 266
Moraleda, G., Saputelli, J., Aldrich, C. E., Averett, D., Condreay, L., & Mason, W. S. (1997) · Journal of Virology · doi:10.1128/jvi.71.12.9392-9399.1997 · Cited by 263
Lange, C. M., Bojunga, J., Hofmann, W. P., Wunder, K., Mihm, U., Zeuzem, S., & Sarrazin, C. (2009) · Hepatology · doi:10.1002/hep.23346 · Cited by 255
Santantonio, T., Mazzola, M., Iacovazzi, T., Miglietta, A., Guastadisegni, A., & Pastore, G. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80076-8 · Cited by 242
Liaw, Y., Raptopoulou‐Gigi, M., Cheinquer, H., Sarin, S. K., Tanwandee, T., Leung, N. W. Y., Peng, C., Myers, R. P., Brown, R. S., Jeffers, L. J., et al. (2011) · Hepatology · doi:10.1002/hep.24361 · Cited by 232
Jeng, W.-J., Sheen, I.-S., Chen, Y.-C., Hsu, C.-W., Chien, R.-N., Chu, C.-M., & Liaw, Y.-F. (2013) · Hepatology · doi:10.1002/hep.26549 · Cited by 225
Determinants for Sustained Hbeag Response to Lamivudine Therapy
Chien, R.-N., Yeh, C.-T., Tsai, S.-L., Chu, C.-M., & Liaw, Y.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50458 · Cited by 214
Liaw, Y.-F., Jia, J.-D., Chan, H. L. Y., Han, K. H., Tanwandee, T., Chuang, W. L., Tan, D. M., Chen, X. Y., Gane, E., Piratvisuth, T., et al. (2011) · Hepatology · doi:10.1002/hep.24555 · Cited by 209
Schiff, E. R., Lee, S. S., Chao, Y., Kew Yoon, S., Bessone, F., Wu, S., Kryczka, W., Lurie, Y., Gadano, A., Kitis, G., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.11.040 · Cited by 183
Zoutendijk, R., Reijnders, J. G. P., Brown, A., Zoulim, F., Mutimer, D., Deterding, K., Petersen, J., Peter Hofmann, W., Buti, M., Santantonio, T., et al. (2011) · Hepatology · doi:10.1002/hep.24406 · Cited by 169
Jang, J. W., Choi, J. Y., Kim, Y. S., Woo, H. Y., Choi, S. K., Lee, C. H., Kim, T. Y., Sohn, J. H., Tak, W. Y., & Han, K. (2015) · Hepatology · doi:10.1002/hep.27723 · Cited by 164
Lok, A. S., Trinh, H., Carosi, G., Akarca, U. S., Gadano, A., Habersetzer, F., Sievert, W., Wong, D., Lovegren, M., Cohen, D., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.037 · Cited by 159
HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B
Liaw, Y.-F. (2009) · Hepatology International · doi:10.1007/s12072-009-9140-3 · Cited by 158
Ioannou, G. N. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-5-201103010-00006 · Cited by 156
Fung, S., Kwan, P., Fabri, M., Horban, A., Pelemis, M., Hann, H.-W., Gurel, S., Caruntu, F. A., Flaherty, J. F., Massetto, B., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.028 · Cited by 147
Jonas, M. M., Block, J. M., Haber, B. A., Karpen, S. J., London, W. T., Murray, K. F., Narkewicz, M. R., Rosenthal, P. J., Schwarz, K. B., & McMahon, B. J. (2010) · Hepatology · doi:10.1002/hep.23934 · Cited by 146
Self-citationKim, G., Lee, H. C., Kim, M.-J., Ha, Y., Park, E. J., An, J., Lee, D., Shim, J. H., Kim, K. M., & Lim, Y. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.031 · Cited by 145
Seto, W., Wong, D. K.-H., Fung, J., Huang, F., Liu, K. S.-H., Lai, C., & Yuen, M. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12739 · Cited by 140
Fung, S. K., Wong, F. S.-H., Hussain, M., & Lok, A. S.-F. (2004) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2004.00556.x · Cited by 139
Benaboud, S., Pruvost, A., Coffie, P. A., Ekouévi, D. K., Urien, S., Arrivé, É., Blanche, S., Théodoro, F., Avit, D., Dabis, F., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00514-10 · Cited by 137
Andréani, T., Serfaty, L., Mohand, D., Dernaika, S., Wendum, D., Chazouillères, O., & Poupon, R. Y. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.01.005 · Cited by 132
A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus
Han, L. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i38.4321 · Cited by 127
Siberry, G. K., Jacobson, D. L., Kalkwarf, H. J., Wu, J. W., DiMeglio, L. A., Yogev, R., Knapp, K. M., Wheeler, J., Butler, L., Hazra, R., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ437 · Cited by 125
Parsonage, M., Wilkins, E. G., Snowden, N., Issa, B. G., & Savage, M. (2005) · HIV Medicine · doi:10.1111/j.1468-1293.2005.00318.x · Cited by 115
Mirochnick, M. H., Thomas, T. K., Capparelli, E. V., Zeh, C. E., Holland, D. T., Masaba, R. O., Odhiambo, P., Fowler, M. G., Weidle, P. J., & Thigpen, M. C. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01117-08 · Cited by 115
Jonas, M. M., Chang, M., Sokal, E. M., Schwarz, K. B., Kelly, D. A., Kim, K. M., Ling, S. C., Rosenthal, P. J., Orăşeanu, D., Reynolds, L., et al. (2015) · Hepatology · doi:10.1002/hep.28015 · Cited by 113
Self-citationZacharakis, G., Koskinas, J. S., Kotsiou, S., Papoutselis, M. K., Tzara, F., Vafeiadis, N., Archimandritis, A. J., & Papoutselis, K. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20434 · Cited by 107
Prevention of Vertical Transmission of Hepatitis B
Kubo, A., Shlager, L., Marks, A. R., Lakritz, D., Beaumont, C., Gabellini, K., & Corley, D. A. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2529 · Cited by 106
Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy
Summers, J. W., & Mason, W. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307422100 · Cited by 99
Wong, G. L., Tse, Y., Wong, V. W., Yip, T. C., Tsoi, K. K., & Chan, H. L. (2015) · Hepatology · doi:10.1002/hep.27894 · Cited by 94
Lim, Y., Yoo, B. C., Byun, K. S., Kwon, S. Y., Kim, Y. J., An, J., Lee, H. C., & Lee, Y. S. (2015) · Gut · doi:10.1136/gutjnl-2014-308435 · Cited by 93
Gish, R. G., Clark, M. D., Kane, S. D., Shaw, R. E., Mangahas, M., & Baqai, S. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.04.008 · Cited by 88
Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B
Mauss, S., Berger, F., Filmann, N., Hueppe, D., Henke, J., Hegener, P., Athmann, C., Schmutz, G., & Herrmann, E. M. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.03.030 · Cited by 86
Berg, T., Zoulim, F., Moeller, B., Trinh, H. N., Marcellin, P., Chan, S., Kitrinos, K. M., Dinh, P. V., Flaherty, J. F., McHutchison, J. G., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.024 · Cited by 85
Viganò, M., Paggi, S., Lampertico, P., Fraquelli, M., Massironi, S., Ronchi, G., Rigamonti, C., Conte, D., & Colombo, M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04722.x · Cited by 83
Fung, J., Lai, C., Tanaka, Y., Mizokami, M., Yuen, J., Wong, D. K.-H., & Yuen, M. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.200 · Cited by 82
Liu, F., Wang, L., Li, X. Y., Liu, Y. D., Wang, J. B., Zhang, Z. H., & Wang, Y. Z. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06492.x · Cited by 82
Kim, S. S., Hwang, J. C., Lim, S. G., Ahn, S. J., Cheong, J. Y., & Cho, S. W. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.145 · Cited by 78
Self-citationJonas, M. M., Lok, A. S.-F., McMahon, B. J., Brown, R. S., Wong, J. B., Ahmed, A. T., Farah, W. H., Mouchli, M. A., Singh, S., Prokop, L. J., et al. (2015) · Hepatology · doi:10.1002/hep.28278 · Cited by 76
Self-citationChaung, K. T., Ha, N. B., Trinh, H. N., Garcia, R. T., Nguyen, H. A., Nguyễn, K., García, G., Ahmed, A., Keeffe, E. B., & Nguyen, M. H. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31825ceed9 · Cited by 73
Mirochnick, M. H., Taha, T. E., Kreitchmann, R., Nielsen‐Saines, K., Kumwenda, J., Joao, E. C., Pinto, J., Santos, B., Parsons, T. L., Kearney, B. P., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182a921eb · Cited by 72
Seropositivity of hepatitis B e antigen and hepatocellular carcinoma
You, S., Yang, H., & Chen, C. (2004) · Annals of Medicine · doi:10.1080/07853890310021580 · Cited by 59
Sriprayoon, T., Mahidol, C., Ungtrakul, T., Chun‐on, P., Soonklang, K., Pongpun, W., Laohapand, C., Dechma, J., Pothijaroen, C., Auewarakul, C. U., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12743 · Cited by 56
Chou, R., Dana, T., Bougatsos, C., Blazina, I., Khangura, J., & Zakher, B. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2837 · Cited by 53
Tien, C., Xu, J. J., Chan, L. S., Chang, M., Lim, C., Lee, S., Huh, B., Shinada, S., Bae, H., & Fong, T. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3363-4 · Cited by 46
Batırel, A. A., Güçlü, E., Arslan, F., Kocak, F., Karabay, O., Ozer, S., Turanlı, M., & Mert, A. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.09.004 · Cited by 42
Mallet, V. O., Schwarzinger, M., Vallet‐Pichard, A., Fontaine, H., Corouge, M., Sogni, P., & Pol, S. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.11.021 · Cited by 40
Huang, X., Xu, Y., Yang, Q., Chen, J., Zhang, T., Li, Z., Guo, C., Chen, H., Wu, H., & Li, N. (2015) · Scientific Reports · doi:10.1038/srep08528 · Cited by 37
Chang, M., Jeng, W., & Liaw, Y. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.10.023 · Cited by 36
Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis
Ye, X. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i39.6665 · Cited by 36
Kemp, W. W., Levy, M. T., Weltman, M., & Lubel, J. S. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12865 · Cited by 34
The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis.
Cholongitas, Ε., Papatheodoridis, G., Goulis, J., Vlachogiannakos, J., Karatapanis, S., Ketikoglou, J., Vasiliadis, T., Kontos, G., Karlaftis, A., & Akriviadis, E. A. (2015) · PubMed Central · Cited by 27
Histopathological evaluation of Ankaferd blood stopper use in the rabbit septoplasty model
Orhan, İ., Doğan, R., Soylu, E., Aksoy, F., Veyseller, B., Özturan, O., Eşrefoğlu, M., & Aydın, M. Ş. (2014) · International Journal of Pediatric Otorhinolaryngology · doi:10.1016/j.ijporl.2014.11.015 · Cited by 24
HB eAg‐negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Viganò, M., Mangia, G., & Lampertico, P. (2013) · Liver International · doi:10.1111/liv.12401 · Cited by 20
Cited by
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
Lampertico, P., Agarwal, K., Berg, T., Buti, M., Janssen, H. L. A., Papatheodoridis, G., Zoulim, F., & Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.021 · Cited by 5,391
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Self-citationApproved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Karlas, T., Petroff, D., Sasso, M., Fan, J.-G., Mi, Y.-Q., de Lédinghen, V., Kumar, M., Lupsor-Platon, M., Han, K.-H., Cardoso, A. C., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.022 · Cited by 1,275
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
Metadata
- Authors
- Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H.
- Venue
- Hepatology
- Published
- 2015-11-13
- Volume
- 63
- Issue
- 1
- Pages
- 261-283
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2173698250
- Cited by
- 2,006
- References
- 99
- FWCI
- 177.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.